Newfeed

HONG KONG, Feb. 28, 2024 /PRNewswire/ — Akeso (9926.HK) announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody(cadonilimab)combined with standard treatment (chemotherapy +/- bevacizumab) as first-line treatment for recurrent/metastatic cervical cancer h

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: